Latest news and articles about Ivonescimab
Total: 1 articles found
Akeso Biopharma’s ivonescimab has demonstrated a significant survival advantage over traditional PD-1 therapies in a landmark Phase III lung cancer trial. While the results signal a shift toward bispecific antibodies as the new standard, experts caution that further global data and longer follow-up are needed to solidify its dominance.
